Unisom May Benefit From FDA Concerns About Rx Competitors – Chattem
This article was originally published in The Tan Sheet
Executive Summary
Chattem expects recent FDA concerns about the side effects of prescription sleep aids to offer a revenue boost to the Unisom line it recently acquired from Johnson & Johnson
You may also be interested in...
Chattem To Unveil New Products In August, Reports 42 Percent Sales Growth
Chattem reported substantially higher sales growth in its latest quarter from brands it acquired in 2006 than from products it developed, but looks to boost those products' contribution to its growth with the launch of nine line extensions in early 2008
Chattem To Unveil New Products In August, Reports 42 Percent Sales Growth
Chattem reported substantially higher sales growth in its latest quarter from brands it acquired in 2006 than from products it developed, but looks to boost those products' contribution to its growth with the launch of nine line extensions in early 2008
Chattem To Unveil New Products In August, Reports 42 Percent Sales Growth
Chattem reported substantially higher sales growth in its latest quarter from brands it acquired in 2006 than from products it developed, but looks to boost those products' contribution to its growth with the launch of nine line extensions in early 2008